BORSAAI Stock News & Alerts

Latest News Calendar Reports Stocks Sign in

Sign in Try BORSA Plus

BORSAAI Stock News & Alerts

Latest News Calendar Reports Stocks Sign in

Sign in Try BORSA Plus

LIVESPY769.55−0.09%EOD QQQ717.54−0.20%EOD

NVDA229.50−0.37%EOD TSLA352.89−0.34%EOD MS218.88+0.53%EOD BCS27.000.00%EOD CL88.85+0.10%EOD BE266.14+5.29%EOD MCD256.02+0.13%EOD BKR63.83+0.52%EOD T25.70+0.14%EOD C137.75+0.03%EOD LULU100.44−0.17%EOD FICO935.00+0.30%EOD KKR109.60+1.73%EOD NVDA229.50−0.37%EOD TSLA352.89−0.34%EOD MS218.88+0.53%EOD BCS27.000.00%EOD CL88.85+0.10%EOD BE266.14+5.29%EOD MCD256.02+0.13%EOD BKR63.83+0.52%EOD T25.70+0.14%EOD C137.75+0.03%EOD LULU100.44−0.17%EOD FICO935.00+0.30%EOD KKR109.60+1.73%EOD

LIVE MARKET SENTIMENTLIVE33Risk-off-3 24h · 15 bullish · 23 bearish · 62 storiessee the drivers with BORSA Plus →Plus →

← Stocks · in the newsroom

Astrazeneca

$AZN · NYSE · 1 stories in 30 days

The wire on $AZN

newest first · duplicate source posts collapse into one event · direct subject stories only

Corporate6:18 AM

AstraZeneca: other phase III volrustomig trials remain on track

AstraZeneca confirmed that its other phase III trials for volrustomig are proceeding as planned. No further details were disclosed.

neutral 50 · impact 20

Free account · 3 complete views a day

The wire on this name is open. What the tape did about it is one free account away.

One free account opens 3 complete views a day on any story, ticker or report. No card. The wire stays free to read.

News on Price
Earnings read
Flow and ownership
Options context

Create a free account · no card →Start 3 days free · no daily limit →

the wire stays free to read · BORSA Plus: start 3 days free, then $49.99 a year or $9.99 a month

WHAT OPENS

NEWS ON PRICE•• event markersMeasured reactions across timeframes

EARNINGS READ••.•% surpriseGuidance, transcript and tone change

FLOW & OWNERSHIP••••••••••Insiders, institutions and options

OPTIONS CONTEXT•• positioningWhere the market leans into the print

BORSA read on $AZNnews only · not price

50

Neutral0 stories in 24 hours · 1 in 30 days · 0 high impact

Three complete views a dayfree account · no card

Create a free account to open the price reaction, catalysts, earnings, ownership and options context behind any three stories, tickers or reports each day. The wire stays free to read.

Open this with a free account →

BORSA News Sentiment is a news-derived editorial measure, separate from price action and not investment advice.

BORSA News Sentiment is a news-derived editorial measure, separate from price action and not investment advice.

News Calendar Reports Stocks Sign in